Advertisement

Drugs & Aging

, Volume 5, Issue 4, pp 288–299 | Cite as

Epidemiology of Stroke

Importance of Preventive Pharmacological Strategies in Elderly Patients and Associated Costs
  • Ichiro Kawachi
Epidemiology

Summary

Stroke is a major cause of death and disability in developed countries. The incidence of stroke increases exponentially with age, yet, traditionally, many medical practitioners have been reluctant to treat hypertension in older patients. Since 1991, the results of 3 major trials — the British Medical Research Council (MRC) trial of treatment in older adults, the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) and the Systolic Hypertension in the Elderly Program (SHEP) — have conclusively established the benefits of treating older patients (> 60 years) with both diastolic and isolated systolic hypertension. International guidelines for the management of hypertension — including the Fifth Report of the Joint National Committee, the 1993 report of the World Health Organization and the International Society of Hypertension and the second report of the British Hypertension Society Working Party — have all been modified to reflect the emerging evidence concerning the benefits of treating older patients. Cost-effectiveness data are similarly in accord with giving high priority to the treatment of older individuals with hypertension.

Keywords

Adis International Limited Antihypertensive Therapy Systolic Hypertension Working Party Mild Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342–4PubMedCrossRefGoogle Scholar
  2. 2.
    Adelman SM. Economic impact: national survey of stroke. Stroke 1981; 12 Suppl. I: I–69–I–78Google Scholar
  3. 3.
    Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease and stroke: a comparative analysis. Am J Public Health 1980; 70: 1249–60PubMedCrossRefGoogle Scholar
  4. 4.
    Marmot MG, Poulter NR. Primary prevention of stroke. Lancet 1992; 339: 344–7PubMedCrossRefGoogle Scholar
  5. 5.
    Rutan GH, Kuller LH, James PH, et al. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Hypertension 1988; 77: 504–14Google Scholar
  6. 6.
    Bonita R, Beaglehole R, North JDK. Event, incidence and case-fatality rates of cerebrovascular disease in Auckland, New Zealand. Am J Epidemiol 1984; 120: 236–43PubMedGoogle Scholar
  7. 7.
    Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154–83CrossRefGoogle Scholar
  8. 8.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older patients with isolated systolic hypertension. JAMA 1991; 265: 3255–64CrossRefGoogle Scholar
  9. 9.
    Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5PubMedCrossRefGoogle Scholar
  10. 10.
    MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12CrossRefGoogle Scholar
  11. 11.
    Beard K, Bulpitt C, Mascie-Taylor H, et al. Management of elderly patients with sustained hypertension. BMJ 1992; 304: 412–6PubMedCrossRefGoogle Scholar
  12. 12.
    O’Malley K, O’Brien E. Where are the guidelines for treating hypertension in elderly patients? BMJ 1992; 305: 845–6PubMedCrossRefGoogle Scholar
  13. 13.
    Staessen J, Fagard R, van Hoof R, et al. Mortality in various intervention trials in elderly hypertensive patients: a review. Eur Heart J 1988; 9: 215–22PubMedGoogle Scholar
  14. 14.
    Thijs L, Fagard R, Lijnen P, et al. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens 1992; 10: 1103–9PubMedCrossRefGoogle Scholar
  15. 15.
    Kuramoto K, Matsushita S, Kuwajima I, et al. Prospective study on the treatment of mild hypertension in the aged. Jpn Heart J 1981; 22: 75–85PubMedCrossRefGoogle Scholar
  16. 16.
    Management Committee. Treatment of mild hypertension in the elderly: a study initiated and administered by the National Heart Foundation of Australia. Med J Aust 1981; 2: 398–402Google Scholar
  17. 17.
    Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349–54PubMedCrossRefGoogle Scholar
  18. 18.
    Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145–51PubMedCrossRefGoogle Scholar
  19. 19.
    Guidelines Sub-Committee. 1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905–18CrossRefGoogle Scholar
  20. 20.
    Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983–7PubMedCrossRefGoogle Scholar
  21. 21.
    Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993; 307: 107–10PubMedCrossRefGoogle Scholar
  22. 22.
    Bulpitt CJ, Fletcher AE, Amery A, et al. The hypertension in the very elderly trial (HYVET): rationale, methodology and comparison with previous trials. Drugs Aging 1994; 5: 171–83PubMedCrossRefGoogle Scholar
  23. 23.
    Kannel WB. Role of blood pressure in cardiovascular morbidity and mortality. Prog Cardiovasc Dis 1974; 17: 5–24PubMedCrossRefGoogle Scholar
  24. 24.
    Kannel WB, Dawber TR, Sorlie P, et al. Components of blood pressure and risk of atherothrombotic brain infarction: the Framingham Study. Stroke 1976; 7: 327–31PubMedCrossRefGoogle Scholar
  25. 25.
    Shekelle RB, Ostfeld AM, Klawans HL. Hypertension and risks of stroke in an elderly population. Stroke 1974; 5: 71–5PubMedCrossRefGoogle Scholar
  26. 26.
    Miall WE. Systolic or diastolic hypertension — which matters most. Clin Exper Hypertens 1982; A4: 1121–31CrossRefGoogle Scholar
  27. 27.
    Staessen J, Amery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens 1990; 8: 393–405PubMedCrossRefGoogle Scholar
  28. 28.
    Silagy CA, McNeil JJ. Epidemiologic aspects of isolated systolic hypertension and implications for future research. Am J Cardiol 1992; 69: 213–8PubMedCrossRefGoogle Scholar
  29. 29.
    Mann SJ. Systolic hypertension in the elderly: pathophysiology and management. Arch Intern Med 1992; 152: 1977–84PubMedCrossRefGoogle Scholar
  30. 30.
    Kawachi I, Purdie G. The benefits and risks of treating mild to moderate hypertension. NZ Med J 1989; 102: 377–9Google Scholar
  31. 31.
    MacMahon SW, Cutler JA, Furberg CD, et al. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular diseases: a review of randomized controlled trials. Prog Cardiovasc Dis 1986; 29 (11 Suppl.): 99–118PubMedCrossRefGoogle Scholar
  32. 32.
    Amery A, Birkenhager W, Bulpitt C, et al. Syst-Eur: a multicentre trial on the treatment of isolated systolic hypertension in the elderly — objectives, protocol and organisation. Aging 1992; 3: 287–302Google Scholar
  33. 33.
    Systolic Hypertension in the Elderly’s Collaborative Group Coordinating Center. Systolic hypertension in the elderly: Chinese trial (Syst-China) — interim report. Chinese Journal of Cardiology 1992; 20: 270–5Google Scholar
  34. 34.
    Joffres MR, Hamet P, Rabkin SW, et al. On behalf of the Canadian Heart Health Services Task Group: prevalence, control and awareness of high blood pressure among Canadian adults. Can Med Assoc J 1992; 146: 1997–2005Google Scholar
  35. 35.
    Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension: the Framingham study. Circulation 1986; 61: 1179–82CrossRefGoogle Scholar
  36. 36.
    Van Loo JM, Peer PG, Thien TA. Twenty-five minutes between blood pressure readings: the influence on prevalence rates of isolated systolic hypertension. J Hypertens 1986; 4: 631–5PubMedCrossRefGoogle Scholar
  37. 37.
    Colandrea MA, Friedman GD, Nichaman MZ, et al. Systolic hypertension in the elderly: an epidemiologic assessment. Circulation 1970; 41: 239–45PubMedCrossRefGoogle Scholar
  38. 38.
    Ruddy MC, Bialy GB, Malka ES, et al. The relationship of plasma renin activity to clinic and ambulatory blood pressure in elderly people with isolated systolic hypertension. J Hypertens 1988; 6 (4 Suppl.): S412–S415Google Scholar
  39. 39.
    Applegate WB, Davis BR, Black RH, et al. Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) Cohort. J Am Geriatr Soc 1991; 39: 1057–64PubMedGoogle Scholar
  40. 40.
    Kaplan NM. The promises and perils of treating the elderly hypertensive. Am J Med Sei 1993; 305: 183–97CrossRefGoogle Scholar
  41. 41.
    Beers MH, Ouslander JG. Risk factors in geriatric drug prescribing: a practical guide to avoiding problems. Drugs 1989; 37: 105–12PubMedCrossRefGoogle Scholar
  42. 42.
    Strandgaard S. Cerebral blood flow and antihypertensive drugs in the elderly. Acta Med Scand 1983; 676 (Suppl.): 103–9Google Scholar
  43. 43.
    Oster JR, Materson BJ. Pseudohypertension: an update. Cardiovasc Risk Factors 1992; 2: 112–20Google Scholar
  44. 44.
    Col N, Fanale JE, Kronholm P. The role of medication non-compliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990; 150: 841–5PubMedCrossRefGoogle Scholar
  45. 45.
    Goldstein G, Materson B, Cushman WC, et al. Treatment of hypertension in the elderly, II: cognitive and behavioral function — results of a Department of Veterans Affairs Cooperative Study. Hypertension 1990; 15: 361–9PubMedCrossRefGoogle Scholar
  46. 46.
    Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114: 956–66PubMedGoogle Scholar
  47. 47.
    Curb JD, Borhani NO, Blaszkowski TP, et al. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA 1985; 253: 3263–8PubMedCrossRefGoogle Scholar
  48. 48.
    Schocken DD, Roth GS. Reduced ß-adrenergic receptor concentrations in aging man. Nature 1977; 267: 856–8PubMedCrossRefGoogle Scholar
  49. 49.
    Applegate WB. Hypertension in elderly patients. Ann Intern Med 1989; 291: 901–15Google Scholar
  50. 50.
    Applegate WB, Phillips HL, Schnaper H, et al. A randomized, controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in elderly females. Arch Intern Med 1991; 151: 1817–23PubMedCrossRefGoogle Scholar
  51. 51.
    Black HR. Age-related issues in the treatment of hypertension. Am J Cardiol 1993; 72: 10H–13HPubMedCrossRefGoogle Scholar
  52. 52.
    Johnston GD. Selecting appropriate antihypertensive drug dosages. Drugs 1994; 47: 567–75PubMedCrossRefGoogle Scholar
  53. 53.
    Bums JF, Weir MR, Oparil S, et al. An assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA 1990; 263: 1507–12CrossRefGoogle Scholar
  54. 54.
    Materson BJ, Oster JR, Michael UF, et al. Dose response to chlorthalidone in patients with mild hypertension: efficacy of a lower dose. Clin Pharmacol Ther 1978; 24: 192–8PubMedGoogle Scholar
  55. 55.
    Vardan S, Mehrotra KG, Moorkherjee S, et al. Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension: a multicenter study. JAMA 1987; 258: 484–8PubMedCrossRefGoogle Scholar
  56. 56.
    Medical Research Council Working Party. Medical Research Council trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97–104CrossRefGoogle Scholar
  57. 57.
    Carlsen JE, Kober L, Torp-Pendersen C, et al. Relationship between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300: 975–8PubMedCrossRefGoogle Scholar
  58. 58.
    Maling TJB, Kawachi I. Minimum effective dosage in the drug treatment of hypertension: a cost effective strategy for prescribers. NZ Med J 1990; 103: 231–3Google Scholar
  59. 59.
    Aldiger JC, Plouin PF, Alexandre JM, et al. Dose dependency of Captopril effects in severely hypertensive patients. J Cardiovasc Pharmacol 1981; 3: 1229–35CrossRefGoogle Scholar
  60. 60.
    Veterans Administration Cooperative Study Group. Captopril: evaluation of low doses, twice daily doses and the addition of diuretic for the treatment of mild to moderate hypertension. Clin Sei 1982; 63: 443s–445sGoogle Scholar
  61. 61.
    Cushman WC, Khatri I, Materson BJ, et al. Treatment of hypertension in the elderly, III: response of isolated systolic hypertension to various doses of hydrochlorothiazide — results of a Department of Veterans Affairs Cooperative Study. Arch Intern Med 1991; 151: 1954–60PubMedCrossRefGoogle Scholar
  62. 62.
    McVeigh GE, Galloway DB, Johnston GD. The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide. BMJ 1988; 297: 95–8PubMedCrossRefGoogle Scholar
  63. 63.
    Passmore AP, Whitehead EM, Crawford V, et al. The antihypertensive and metabolic effects of low and conventional dose cyclopenthiazide in type II diabetics with hypertension. QJ Med 1991; 295: 919–28Google Scholar
  64. 64.
    Fotherby MD, Harper GD, Potter JF. General practitioners’ management of hypertension in elderly patients. BMJ 1992; 305: 750–2PubMedCrossRefGoogle Scholar
  65. 65.
    Weinstein MC, Stason WB. Hypertension: a policy perspective. Cambridge, MA: Harvard University Press, 1976Google Scholar
  66. 66.
    Littenberg B, Garber AM, Sox HC. Screening for hypertension. Ann Intern Med 1990; 112: 191–202Google Scholar
  67. 67.
    Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens 1991; 9: 199–208PubMedCrossRefGoogle Scholar
  68. 68.
    Edelson JT, Weinstein MC, Tosteson AN, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263: 407–13PubMedCrossRefGoogle Scholar
  69. 69.
    Johannesson M, Jönsson B. Cost-effectiveness analysis of hypertension treatment: a review of methodological issues. Health Policy 1991; 19: 55–78PubMedCrossRefGoogle Scholar
  70. 70.
    Kawachi I, Wilson NA. The evolution of antihypertensive therapy. Soc Sei Med 1990; 31: 1239–43CrossRefGoogle Scholar
  71. 71.
    Hjemdahl P, Wiklund IK. Quality of life on antihypertensive therapy: scientific end-point or marketing exercise? J Hypertens 1992; 10: 1437–46PubMedCrossRefGoogle Scholar
  72. 72.
    Kitler ME. Elderly hypertensives and quality of life: some methodological considerations. Eur Heart J 1993; 14: 113–21PubMedCrossRefGoogle Scholar
  73. 73.
    Levine S, Croog SH. What constitutes quality of life? A conceptualization of the dimensions of life quality in healthy populations and patients with cardiovascular disease. In: Wenger NK, Mattson ME, Furberg CD, editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: LeJacq Communications, 1984: 46–58Google Scholar
  74. 74.
    Croog SH, Levine S, Testa MA, et al. Effects of antihypertensive therapy on quality of life. N Engl J Med 1986; 314: 1657–64PubMedCrossRefGoogle Scholar
  75. 75.
    Fletcher AE, Bulpitt CJ, Chase DM, et al. Quality of life with three antihypertensive treatments: Cilazapril, atenolol, nifedipine. Hypertension 1992; 19: 499–507PubMedCrossRefGoogle Scholar
  76. 76.
    Palmer AJ, Fletcher AE, Rudge PJ, et al. Quality of life in hypertensives treated with atenolol or Captopril: a doubleblind crossover trial. J Hypertens 1992; 10: 1409–16PubMedCrossRefGoogle Scholar
  77. 77.
    Croog SH, Kong BW, Levine S, et al. Hypertensive black men and women: quality of life and effects of antihypertensive medications. Arch Intern Med 1990; 150: 1733–41PubMedCrossRefGoogle Scholar
  78. 78.
    Wassertheil-Smoller S, Blaufox MD, TAIM Research Group. Effect of antihypertensives on sexual function and quality of life: the TAIM study. Ann Intern Med 1991; 114: 613–20PubMedGoogle Scholar
  79. 79.
    Testa MA, Anderson RB, Nackley JA, et al. Quality of life and antihypertensive therapy in men. A comparison of Captopril and enalapril. N Engl J Med 1993; 328: 907–13PubMedCrossRefGoogle Scholar
  80. 80.
    deLame PA, Droussin AM, Thomson M, et al. The effects of enalapril on hypertension and quality of life. Acta Cardiol 1989; 44: 289–302Google Scholar
  81. 81.
    Steiner SS, Friedhoff AJ, Wilson BL, et al. Antihypertensive therapy and quality of life: a comparison of atenolol, Captopril, enalapril, and propranolol. J Hum Hypertens 1990; 4: 217–25PubMedGoogle Scholar
  82. 82.
    Task Force on the Availability of Cardiovascular Drugs to the Medically Indigent. Report of the task force on the availability of cardiovascular drugs to the medically indigent. Circulation 1992; 85: 850–60Google Scholar
  83. 83.
    Stason WB. Cost and quality trade-offs in the treatment of hypertension. Hypertension 1989; 13 (Suppl. I): I–145–I–148Google Scholar
  84. 84.
    Croog SH, Elias MF, Colton T, et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertens 1994; 7: 329–39PubMedGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Ichiro Kawachi
    • 1
  1. 1.Department of Health and Social BehaviorHarvard School of Public HealthBostonUSA

Personalised recommendations